2 November 2000
Since 1986, Intervet Norbio has worked on the development of efficacious and safe vaccines against Infectious Pancreativ Necrosis (IPN). By closely co-operating with research groups within the University of Bergen, The Institute of Marine Research and the Veterinary Institute a new generation of fish vaccines based on modern biotechnology has successfully been developed.
The recombinant produced protein, VP2 is used as an antigen in various vaccine formulations and tested in a series of effect and safety studies under both laboratory and field conditions.
The Research Council of Norway has supported the research and development work through various research and scholarship programmes.
The distribution and significance of Infectious Pancreatic Necrosis in Norwegian seawater salmon farms.
Commissioned by Intervet Norbio, the Vetirinary Institute and the governmental veterinary laboratories in Trondheim and Oslo have performed epidemiolgoical studies in order to accurately define the geographical spread and accumulated losses due to IPN in teh NOrwegian salmon farming industry. The studies were carried out in the period 1994-1998, and cover each year 26-36 million salmon from some 120-160 different farming sites. In the period 1997-1998, 60-70% of the fish in the investigation were vaccinated with different types of IPN vaccines.
